Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

[1]  M. Parmar,et al.  Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial , 2011, Lancet.

[2]  D. Amadori,et al.  Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA) , 2011 .

[3]  P. Royston,et al.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt , 2011, Statistics in medicine.

[4]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[5]  Patrick Royston,et al.  Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit , 2011, Trials.

[6]  J. D. de Bono,et al.  New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway , 2011, Clinical Cancer Research.

[7]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[8]  W. Dahut,et al.  An update on androgen deprivation therapy for prostate cancer. , 2010, Endocrine-related cancer.

[9]  O. Sartor,et al.  Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer. , 2010, Clinical genitourinary cancer.

[10]  F. Saad,et al.  Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies , 2010, Expert review of anticancer therapy.

[11]  B. Elewski,et al.  Chemoprevention of Nonmelanoma Skin Cancer With Celecoxib: A Randomized, Double-Blind, Placebo-Controlled Trial , 2010, Journal of the National Cancer Institute.

[12]  D. Kerr,et al.  Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Machiels,et al.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.

[14]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[15]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[16]  H. Parnes,et al.  Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Parmar,et al.  Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial , 2009, Trials.

[18]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[19]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[20]  M. Parmar,et al.  Speeding up the Evaluation of New Agents in Cancer , 2008, Journal of the National Cancer Institute.

[21]  C. Bokemeyer,et al.  Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  C. Parker,et al.  Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. , 2007, The Lancet. Oncology.

[23]  J. Manola,et al.  Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Melvin,et al.  Effects of estrogen with and without progestin on urinary incontinence , 2005, Journal of Family Planning and Reproductive Health Care.

[25]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[26]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[27]  F. D. De Braud,et al.  Irinotecan combined with infusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Wilt,et al.  226: Prevalence and Correlates of Prostatitis in a Large Community-Based Cohort of Older Men , 2004 .

[29]  G. Piazza,et al.  Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention. , 2004, The Journal of urology.

[30]  Patrick Royston,et al.  Novel designs for multi‐arm clinical trials with survival outcomes with an application in ovarian cancer , 2003, Statistics in medicine.

[31]  R. Roberts,et al.  A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. , 2002, Mayo Clinic proceedings.

[32]  B. Levin,et al.  The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. , 2000, The New England journal of medicine.

[33]  K. Seibert,et al.  Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. , 2000, Cancer research.

[34]  B. Seidenberg.  COX-2 inhibitors , 1999, The Lancet.

[35]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). , 1998, Journal of the National Cancer Institute.

[36]  R. Coffey,et al.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. , 1994, Gastroenterology.

[37]  H. Scher,et al.  Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  W. Frishman.  Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention , 2006 .

[39]  Randall Harris,et al.  Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. , 2000, Oncology reports.

[40]  M. Taketo.  Cyclooxygenase-2 inhibitors in tumorigenesis (part I). , 1998, Journal of the National Cancer Institute.